Paper40926993
Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.
Zhang Y and 3 others. Front Pharmacol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway. Papers, record 40926993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40926993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References256
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24947038 | Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. | Virol J | 2014 | https://conductscience.org/library/papers/24947038 | PubMed |
| 2 | 31892693 | Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect. | Med Sci Monit | 2020 | https://conductscience.org/library/papers/31892693 | PubMed |
| 3 | 38584523 | 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway. | Acta Biochim Biophys Sin (Shanghai) | 2024 | https://conductscience.org/library/papers/38584523 | PubMed |
| 4 | 38992397 | Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/38992397 | PubMed |
| 5 | 38816668 | Signaling pathways in liver cancer: pathogenesis and targeted therapy. | Mol Biomed | 2024 | https://conductscience.org/library/papers/38816668 | PubMed |
| 6 | 38936522 | Progress in the development of modulators targeting Frizzleds. | Pharmacol Res | 2024 | https://conductscience.org/library/papers/38936522 | PubMed |
| 7 | 38909826 | Mechanistic insights into xanthomicrol as the active anti-HCC ingredient of Phytolacca acinosa Roxb.: A network pharmacology analysis and transcriptomics integrated experimental verification. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/38909826 | PubMed |
| 8 | 36118529 | Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis. | J Cancer | 2022 | https://conductscience.org/library/papers/36118529 | PubMed |
| 9 | 34690755 | Gallic Acid Suppressed Tumorigenesis by an LncRNA MALAT1-Wnt/β-Catenin Axis in Hepatocellular Carcinoma. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34690755 | PubMed |
| 10 | 32071301 | Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/32071301 | PubMed |
| 11 | 39197803 | Jiedu Xiaozheng Yin extract targets cancer stem cells by Wnt signaling pathway in colorectal cancer. | J Ethnopharmacol | 2025 | https://conductscience.org/library/papers/39197803 | PubMed |
| 12 | 25917329 | Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. | FASEB J | 2015 | https://conductscience.org/library/papers/25917329 | PubMed |
| 13 | 38823657 | Qizhu anticancer prescription enhances immunosurveillance of liver cancer cells by regulating p21-dependent secretory phenotypes. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/38823657 | PubMed |
| 14 | 34330066 | Koumine modulates spinal microglial M1 polarization and the inflammatory response through the Notch-RBP-Jκ signaling pathway, ameliorating diabetic neuropathic pain in rats. | Phytomedicine | 2021 | https://conductscience.org/library/papers/34330066 | PubMed |
| 15 | 33984593 | Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. | Phytomedicine | 2021 | https://conductscience.org/library/papers/33984593 | PubMed |
| 16 | 29775121 | A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China. | Integr Cancer Ther | 2018 | https://conductscience.org/library/papers/29775121 | PubMed |
| 17 | 34559118 | Efficacy of erzhu jiedu recipe on hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind, placebo-controlled clinical trial. | Medicine (Baltimore) | 2021 | https://conductscience.org/library/papers/34559118 | PubMed |
| 18 | 37692966 | Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway. | Am J Transl Res | 2023 | https://conductscience.org/library/papers/37692966 | PubMed |
| 19 | 30094101 | Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin β2/FAK signaling pathway in ovarian cancer. | Am J Cancer Res | 2018 | https://conductscience.org/library/papers/30094101 | PubMed |
| 20 | 35388357 | Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. | J Hepatocell Carcinoma | 2022 | https://conductscience.org/library/papers/35388357 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42305489 | The anti-migratory effect of curcumin in colorectal cancer involves IKKβ/NF-κB/Snail-mediated EMT inhibition. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42305489 | PubMed |
| 41981689 | The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome. | Chin Med | 2026 | https://conductscience.org/library/papers/41981689 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40926993
GET https://conductscience.org/api/papers/v1/40926993/references?page=2